Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report

作者：Mercè Brunet, Teun van Gelder, Anders Åsberg, Vincent Haufroid, Dennis A. Hesselink, Loralie J. Langman, F. Lemaı̂tre, Pierre Marquet, Christoph Seger, Maria Shipkova, Alexander A. Vinks, Pierre Wallemacq, Eberhard Wieland, Jean‐Baptiste Woillard, Markus J. Barten, Klemens Budde, Helena Colom, Maja‐Theresa Dieterlen, Laure Elens, Kamisha L. Johnson‐Davis, Paweł K. Kunicki, Iain MacPhee, Satohiro Masuda, Binu Mathew, Olga Millán, Tomoyuki Mizuno, Dirk Jan A. R. Moes, Caroline Monchaud, Ofelia Noceti, T. Pawiński, Nicolas Picard, Ron HN van Schaik, Claudia Sommerer, Nils Tore Vethe, Brenda C. M. de Winter, Uwe Christians, Stein Bergan · 发表于：Therapeutic Drug Monitoring · 年份：2019 · DOI：10.1097/ftd.0000000000000640 · 被引用次数：710 · 研究领域：Renal Transplantation Outcomes and Treatments、Pharmacological Effects and Toxicity Studies、Hematopoietic Stem Cell Transplantation

Ten years ago, a consensus report on the optimization of tacrolimus was published in this journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicity (IATDMCT) decided to issue an updated consensus report considering the most relevant advances in tacrolimus pharmacokinetics (PK), pharmacogenetics (PG), pharmacodynamics, and immunologic biomarkers, with the aim to provide analytical and drug-exposure recommendations to assist TDM professionals and clinicians to individualize tacrolimus TDM and treatment. The consensus is based on in-depth literature searches regarding each topic that is addressed in this document. Thirty-seven international experts in the field of TDM of tacrolimus as well as its PG and biomarkers contributed to the drafting of sections most relevant for their expertise. Whenever applicable, the quality of evidence and the strength of recommendations were graded according to a published grading guide. After iterated editing, the final version of the complete document was approved by all authors. For each category of solid organ and stem cell transplantation, the current state of PK monitoring is discussed and the specific targets of tacrolimus trough concentrations (predose sample C0) are presented for subgroups of patients along with the grading of these recommendations. In addition, tacrolimus area under the concentration-time curve determination is proposed as the b...